Mathilde Tjepkema , Sufia Amini , Martin Schipperus
{"title":"Risk of thrombosis with thrombopoietin receptor agonists for ITP patients: A systematic review and meta-analysis","authors":"Mathilde Tjepkema , Sufia Amini , Martin Schipperus","doi":"10.1016/j.critrevonc.2022.103581","DOIUrl":null,"url":null,"abstract":"<div><p>One possible side effect of thrombopoietin receptor<span> agonists in immune thrombocytopenia is thrombosis. Our aim is to systematically review whether patients with ITP that were treated with a TPO-RA have an increased risk for thrombosis as compared to ITP patients without TPO-RA. Patients in the intervention group were required to receive TPO-RA therapy. The primary outcome was the incidence of thromboembolic<span> events. Eleven studies were included in the pooled analysis. More thromboembolic events were noted in the TPO-RA group than in the control group: 25 compared to 4. Ten out of 11 studies showed a relative risk greater than 1. However, none of these individual risk ratios was statistically significant. The meta-analysis showed a RR of 1.82 [95 % CI 0.78–4.24]. Our findings indicate there is a non-significant higher chance of thrombosis in ITP patients with TPO-RA treatments versus ITP patients without TPO-RA treatment.</span></span></p></div>","PeriodicalId":11358,"journal":{"name":"Critical reviews in oncology/hematology","volume":"171 ","pages":"Article 103581"},"PeriodicalIF":5.6000,"publicationDate":"2022-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"14","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Critical reviews in oncology/hematology","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S1040842822000051","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"HEMATOLOGY","Score":null,"Total":0}
引用次数: 14
Abstract
One possible side effect of thrombopoietin receptor agonists in immune thrombocytopenia is thrombosis. Our aim is to systematically review whether patients with ITP that were treated with a TPO-RA have an increased risk for thrombosis as compared to ITP patients without TPO-RA. Patients in the intervention group were required to receive TPO-RA therapy. The primary outcome was the incidence of thromboembolic events. Eleven studies were included in the pooled analysis. More thromboembolic events were noted in the TPO-RA group than in the control group: 25 compared to 4. Ten out of 11 studies showed a relative risk greater than 1. However, none of these individual risk ratios was statistically significant. The meta-analysis showed a RR of 1.82 [95 % CI 0.78–4.24]. Our findings indicate there is a non-significant higher chance of thrombosis in ITP patients with TPO-RA treatments versus ITP patients without TPO-RA treatment.
血小板生成素受体激动剂对免疫性血小板减少症的一个可能的副作用是血栓形成。我们的目的是系统地回顾ITP患者与没有TPO-RA的ITP患者相比，接受TPO-RA治疗的ITP患者血栓形成的风险是否增加。干预组患者需接受TPO-RA治疗。主要终点是血栓栓塞事件的发生率。汇总分析纳入了11项研究。TPO-RA组的血栓栓塞事件比对照组多:25例比4例。11项研究中有10项显示相对风险大于1。然而，这些个体风险比都没有统计学意义。meta分析显示RR为1.82 [95% CI 0.78-4.24]。我们的研究结果表明，与未接受TPO-RA治疗的ITP患者相比，接受TPO-RA治疗的ITP患者血栓形成的机会没有明显增加。
期刊介绍：
Critical Reviews in Oncology/Hematology publishes scholarly, critical reviews in all fields of oncology and hematology written by experts from around the world. Critical Reviews in Oncology/Hematology is the Official Journal of the European School of Oncology (ESO) and the International Society of Liquid Biopsy.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
